CD38 and plasma cell myeloma: For instance, a CD38/CD3 Bi-Ab (ISB-1342) that targets tumor cells (via CD38) and immune effector T cells (via CD3) is in phase II for relapsed/refractory multiple myeloma (R/R MM) (NCT033309111); the putative efficacy of ISB-1342 in CLL remains to be tested.